Transcenta Holding Limited
創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

VOLUNTARY ANNOUNCEMENT

TRANSCENTA TO PRESENT AT THE 36TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE

This announcement is made by Transcenta Holding Limited (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update. Capitalized terms used herein but not otherwise defined shall have the same meaning ascribed thereto in the announcement of the Company dated January 22, 2026 (the "**January Announcement**").

The board of directors of the Company (the "**Board**") is pleased to announce that members of its senior leadership team, namely Dr. Xueming Qian, Founder, Chairman and CEO, Mr. Weiwei Liang, SVP, Business Development and Corporate Strategy, Acting CFO, and Mr. Tyler Marciniak, SVP, Capital Markets, Investor Relations and Corporate Communications, will participate in the 36th Annual Oppenheimer Healthcare Life Sciences Conference (February 25-26, Eastern Time), with the Company virtual presentation to be held at 12:00 pm Eastern Time on February 26, 2026.

During the conference, management will discuss with investors its strategic efforts for 2026 and provide updates on its ongoing business development and operational excellence initiatives. These updates include:

- After successfully executing a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. in December 2025, the Company has now received the upfront payments pursuant to the collaboration;

- Further to the updates provided in the January Announcement, the Company has:

  - advanced discussions for the development and commercialization of its lead asset with multiple global and regional pharmaceutical companies, with several parties now conducting due-diligence reviews and/or proceeding with contracting or term sheet-level negotiations covering global and regional collaboration scopes;

  - garnered interest from global and regional investment institutions, with several currently engaged in active contracting or term sheet-level negotiations, in respect of funding for the Company and multiple assets;

- implemented resource alignment measures resulting in (i) headcount reduction of approximately 16% as of December 31, 2025 compared to December 31, 2024, and (ii) expense reduction of approximately 34% across labor, R&D and other operating expenses as of December 31, 2025 compared to December 31, 2024. These measures have resulted in an estimated cost saving of RMB19 million for Q4, 2025, compared to Q4, 2024, thereby improving operating efficiency and extending the Company's cash runway;

- successfully negotiated repayment extensions and/or revised schedules with three suppliers for total of approximately RMB10 million, extending payment dates by over 130 days on average. These measures have been implemented as part of the Company's ongoing liquidity and working capital management measures following the Disclaimer of Opinion, and have contributed to improved short-term cash flow of the Company while ensuring uninterrupted operations; and

- maintained positive relationships with its banking partners to support the renewal and extension of loan facilities. Since the last update in October 2025, the Company has renewed RMB77 million of banking facilities and secured RMB15 million of new facilities, and is in discussions with three additional financial institutions regarding further credit lines. These measures, if completed, would improve the Company's capital flexibility and provide support for day-to-day operations and R&D expenditures.

By Order of the Board
Transcenta Holding Limited
Xueming Qian
Executive Director, Chairman and
Chief Executive Officer

Hong Kong, February 24, 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Xueming Qian as executive Director, chairman and chief executive officer, Dr. Li Xu as non-executive Director and Mr. Jiasong Tang, Mr. Zhihua Zhang, Dr. Kumar Srinivasan and Ms. Helen Wei Chen as independent non-executive Directors.